What's New

News

2014/11/28
Nippon Kayaku launches Infliximab BS for I.V. Infusion 100mg “NK”, an anti-human TNF-α monoclonal antibody, in Japan
2014/09/30
Updated information of CSR
2014/07/15
Details concerning the Relocation of the Head Office
2014/07/04
Nippon Kayaku Announces Marketing Approval in Japan of Infliximab Biosimilar Monoclonal Antibody.
2014/05/19
Notice of Head Office Relocation
2014/03/12
Updated information of CSR
2014/01/30
Nippon Kayaku launches embolic microspheres, “HepaSphere® Microspheres” and “Embosphere® Microspheres” in Japan
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR